THE DEAL, AT A GLANCE
From the announcementShenzhen Boyin Biotechnology
01Who is involvedBacked by L'Oréal's BOLD investment fund, a Walgreens–Guangzhou Pharmaceutical investment fund, Guangxin Fund, Shenzhen Institute of Advanced TechnologyFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedShenzhen Boyin Biotechnology raised $27.5M Series A, announced 2026-11-12From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersShenzhen Boyin Biotechnology raised $27.5M in a Series A round, placing it at the 56th percentile by size among tracked Unclassified rounds.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Shenzhen Boyin Biotechnology · Financing Record
Explore source-linked visual explanations for Shenzhen Boyin Biotechnology. Unsupported claims are withheld while source review continues.
Record 16003 · Recorded date: 2026-11-12
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →